tbuckley/cabot-search huggingface dataset:
EP13.01-12 Validation of LIPI index in SCLC
Authors: P. Cruz, B. Riesco Montes, L. Fernandez Franco, S. Falagan, L.E. Chara, S. Simon Alonso, O. Higuera, S. Cerezo, L. Gutierrez-Sainz, J. Villamayor, R. Galan Moral, J.C. Villa, R. Alvarez Cabellos, A.K. Santos Rodriguez, R. Lopez Bajo, J. Portela, M. Serrano, J.R. Muñoz-Rodriguez
Journal: Journal of Thoracic Oncology (2023)
OA20.06 Quantification of Pathologically Assessed Lymph Node Area in Lung Cancer Resection Using Deep Learning
Authors: A. Lametti, É. Pichette, C. Ochs, A. Rajaram, R. Rayes, J. Cools-Lartigue, J. Spicer, S. Camilleri-Broët, A. Spatz, P.O. Fiset
Journal: Journal of Thoracic Oncology (2023)
OA20.03 Spatially Resolved Transcriptomic Characterisation of High-Risk Morphologies in Lung Adenocarcinoma
Authors: H. Williams, A. Pancheva, K. Rakovic, H. Leslie, C. Wood, L. Officer-Jones, N. Jamieson, C. Miller, J. Le Quesne
Journal: Journal of Thoracic Oncology (2023)
OA15.05 Lung Immune Prognostic Index Predicts Outcomes from Upfront Chemotherapy + Immunotherapy +/- Antiangiogenic in Advanced NSCLC
Authors: M. Roulleaux Dugage, T. Gorria, A. Rochand, L.-M. Garcin, S. Oudard, V. Albarrán-Artahona, J.C. Laguna, I. Nalda, F.J. Muñoz-Carrillo, L. Aguilar, A. Arcocha, L. Lupinacci, C. Teixidó, B. Besse, L. Mezquita, E. Auclin
Journal: Journal of Thoracic Oncology (2023)
MA11.10 Intravenous Indocyanine Green Administration Provides Sufficient Margins in Pulmonary Segmentectomy
Authors: T. Ochi, Y. Sakairi, Y. Sata, T. Toyoda, T. Inage, K. Tanaka, H. Suzuki, Y. Matsui, M. Ota, I. Yoshino
Journal: Journal of Thoracic Oncology (2023)
WS08.07 Evaluation of a Risk-sharing Agreement for Atezolizumab Treatment in NSCLC Patients: A Strategy to Improve Access in Low Income Countries
Authors: O. Arrieta, M. Ramos-Ramirez, H. Garces-Flores, L.A. Cabrera-Miranda, A. Valencia-Velarde, A. Frias-Gasga, H. Soto-Molina
Journal: Journal of Thoracic Oncology (2023)
Patient partnership at BMJ
Authors: Emma Doble, Amy Price, Sophia Walker, Sophie Cook, Kamran Abbasi
Journal: BMJ (2023)

Pressures on health systems around the world continue to mount, and staff shortages, long waiting lists, and delays for essential treatment are putting an unprecedented strain on health services. 1 In the UK, National Voices, a leading patient organisation, argues that the UK's current healthcare workforce crisis is "badly impacting people's experience of health and care." 2 The experience of patients and the public can and should contribute to finding solutions to the pressure on the health services.But their voices are often marginalised.
Haploinsufficient Transcription Factors in Myeloid Neoplasms
Authors: Tanner C. Martinez, Megan E. McNerney
Journal: Annual Review of Pathology Mechanisms of Disease (2023)

Many transcription factors (TFs) function as tumor suppressor genes with heterozygous phenotypes, yet haploinsufficiency generally has an underappreciated role in neoplasia. This is no less true in myeloid cells, which are normally regulated by a delicately balanced and interconnected transcriptional network. Detailed understanding of TF dose in this circuitry sheds light on the leukemic transcriptome. In this review, we discuss the emerging features of haploinsufficient transcription factors (HITFs). We posit that: (
Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease
Authors: Hyeok-Hee Lee, Han Ah Lee, Eun-Jin Kim, Hwi Young Kim, Hyeon Chang Kim, Sang Hoon Ahn, Hokyou Lee, Seung Up Kim
Journal: Gut (2023)

Objective We explored clinical implications of the new definition of metabolic dysfunction-associated steatotic liver disease (MASLD) by assessing its prevalence and associated cardiovascular disease (CVD) risk. Design From nationwide health screening data, we identified 9 775 066 adults aged 20–79 who underwent health examination in 2009. Participants were categorised into four mutually exclusive groups: (1) MASLD; (2) MASLD with increased alcohol intake (MetALD); (3) MASLD with other combined aetiology (the three collectively referred to as MASLD/related steatotic liver disease (SLD)); and (4) no MASLD/related SLD. SLD was determined by fatty liver index ≥30. The primary outcome was CVD event, defined as a composite of myocardial infarction, ischaemic stroke, heart failure or cardiovascular death. Results The prevalence of MASLD, MetALD and MASLD with other combined aetiology was 27.5%, 4.4% and 1.5%, respectively. A total of 8 808 494 participants without prior CVD were followed up for a median of 12.3 years, during which 272 863 CVD events occurred. The cumulative incidence and multivariable-adjusted risk of CVD were higher in participants with MASLD/related SLD than in those without (HR 1.38 (95% CI 1.37 to 1.39)). Multivariable-adjusted HR (95% CI) of CVD events was 1.39 (1.38 to 1.40) for MASLD, 1.28 (1.26 to 1.30) for MetALD and 1.30 (1.26 to 1.34) for MASLD with other combined aetiology compared to the absence of any of these conditions. CVD risk was also higher in participants with metabolic dysfunction-associated fatty liver disease or non-alcoholic fatty liver disease than in those without the respective condition. Conclusion Over one-third of Korean adults have MASLD/related SLD and bear a high CVD risk.
EP12.01-75 Good Results of Osimertinib in a Patient with EGFR (L861Q) and MET Amplification NSCLC: A Case Report
Authors: I.R. González-Espinoza, S. Sánchez-Sosa, A. Castro-Ponce, C. Peñaloza-Coronas, S. Montilla-Fonseca, G. Cuauro-Ruiz, D.A. Juárez-Salazar, M. Chiquillo-Domínguez, G. Juárez-Salazar, M.d.J. González-Blanco, J.M. Aguilar-Priego, C. Cordero-Vargas, E. Miguel-Cruz, J.S. Montiel-Castro, A.I. Nieva-Silva
Journal: Journal of Thoracic Oncology (2023)
Corrigendum to “Development and validation of the AMMON-OHE model to predict risk of overt hepatic encephalopathy occurrence in outpatients with cirrhosis” [J Hepatol 79(4) (2023 Oct) 967–976]
Authors: Maria Pilar Ballester, Thomas H. Tranah, Lorenz Balcar, Alessandra Fiorillo, Javier Ampuero, Annarein J.C. Kerbert, Karen L. Thomsen, María Desamparados Escudero, Mattias Mandorfer, Thomas Reiberger, Debbie L. Shawcross, Manuel Romero-Gómez, Carmina Montoliu, Juan Antonio Carbonell-Asins, Rajiv Jalan
Journal: Journal of Hepatology (2023)
OA09.04 ILLUMINATE: Efficacy and Safety of Durvalumab-Tremelimumab and Chemotherapy in EGFR Mutant NSCLC Following Progression on EGFR Inhibitors
Authors: C. Lee, B.-C. Liao, S. Subramaniam, C.-H. Chiu, A. Mersiades, C.-C. Ho, C. Brown, C.-L. Lai, B.G.M. Hughes, T.-Y. Yang, K. O'Byrne, Y.-H. Luo, S. Yip, C.-L. Ho, V. Bray, W.-C. Su, M. Moore, W.-L. Feng, Y.-Y. Bai, M. Stockler, B. Solomon, T. John, J.C.-H. Yang
Journal: Journal of Thoracic Oncology (2023)
MA14.05 Tumor Tissue and Plasma EGFR Exon 20 Insertion Mutation Status in NSCLC Patients Treated with Sunvozertinib
Authors: M. Wang, Y. Fan, M. Sun, Y. Wang, Y. Zhao, B. Jin, Y. Hu, Z. Han, X. Song, A. Liu, K. Tang, C. Ding, L. Liang, L. Wu, J. Gao, J. Wang, Y. Cheng, J. Zhou, Y. He, X. Dong, Y. Yao, Y. Yu, H. Wang, S. Sun, J. Huang, J. Fang, W. Li, L. Wang, X. Ren, C. Zhou, Y. Hu, D. Zhao, R. Yang, F. Xu, Y. Huang, Y. Pan, J. Cui, Y. Xu, X. Zhu, Y. Shi
Journal: Journal of Thoracic Oncology (2023)
P2.10-01 ALKTERNATE: A Pilot Study Alternating Lorlatinib with Crizotinib in Patients with ALK+ NSCLC and ALK-inhibitor Resistance
Authors: M. Itchins, S. Liang, C. Brown, T. Barnes, G. Marx, V. Chin, S. Kao, P.Y. Yip, A.J. Mersiades, A. Nagrial, V. Bray, G. Peters, S. Parakh, T. John, M. Li, B.T. Li, M. McKay, M. Molloy, K. O'Byrne, C. Lee, A. Gill, B.J. Solomon, N. Pavlakis
Journal: Journal of Thoracic Oncology (2023)
OA15.06 Differences in Pathologic Assessment by MPR Calculation Methods for Multiple Slides of Tumor Bed in SQUAT Trial (WJOG12119L)
Authors: J. Kashima, K. Inamura, A. Hamada, J. Soh, A. Hata, K. Nakamatsu, M. Shimokawa, J. Suzuki, M. Tsuboi, H. Horinouchi, I. Yoshino, M. Tanahashi, S. Toyooka, M. Okada, T. Go, M. Yamashita, Y. Nishimura, N. Yamamoto, K. Nakagawa, T. Mitsudomi, Y. Yatabe
Journal: Journal of Thoracic Oncology (2023)
MA11.11 Drug Tolerant Persister Cells to Neoadjuvant Osimertinib in Resectable Non-small Cell Lung Cancer Harboring EGFR Mutations (NORA)
Authors: J.B. Lee, S.J. Choi, Y.J. Park, K.-H. Park, S.H. Yong, H.S. Shim, B.J. Park, C.Y. Lee, S.K. Cheung, S. Sudhaman, S. Velichko, M. Krainock, H. Sethi, M.C. Liu, M.H. Hong, B.C. Cho, S.M. Lim
Journal: Journal of Thoracic Oncology (2023)
PL03.10 MARS 2: A Multicentre Randomised Trial Comparing (Extended) Pleurectomy Decortication versus No Radical Surgery for Mesothelioma
Authors: E. Lim, D. Waller, K. Lau, J. Steele, A. Pope, C. Ali, R. Bilancia, M. Keni, S. Popat, M. O'Brien, N. Tokaca, N. Maskell, L. Stadon, A. Nakas, D. Fennell, J. Edwards, S. Tenconi, L. Socci, R. Rintoul, K. Wood, A. Stone, D. Muthukumar, C. Ingle, P. Taylor, L. Cove-Smith, R. Califano, Y. Summers, Z. Tasigiannopoulos, A. Bille, R. Shah, L. Fuller, J. Shamash, A. Macnair, T. Mansy, R. Milton, P. Koh, A.A. Ionescu, S. Treece, A. Roy, G. Middleton, A. Kirk, R. Harris, K. Ashton, B. Warnes, E. Bridgeman, K. Joyce, N. Mills, D. Elliott, N. Farrar, E. Stokes, V. Hughes, A. Nicholson, C. Rogers
Journal: Journal of Thoracic Oncology (2023)
MA13.06 Amivantamab, Lazertinib Plus Platinum-based Chemotherapy in EGFR-mutated Advanced NSCLC: Updated Results from CHRYSALIS-2
Authors: S.-H. Lee, B.C. Cho, A.I. Spira, S.-H.I. Ou, S.N. Waqar, S. Shah, L. Trani, P.-L. Chu, M. Thayu, R.E. Knoblauch, J.M. Bauml, M.E. Marmarelis
Journal: Journal of Thoracic Oncology (2023)
WS02.13 PD-L1 Expression Guidance on Sintilimab versus Pembrolizumab in Untreated Advanced NSCLC (CTONG1901)
Authors: S.-Y.M. Liu, J.-Y. Deng, H.-H. Yan, M.-Y. Yang, C.-R. Xu, M.-Y. Zheng, B. Gan, X.-C. Zhang, H.-Y. Tu, J.-J. Yang, H.-J. Chen, B.-C. Wang, Y. Li, Q. Zhou, Y.-L. Wu
Journal: Journal of Thoracic Oncology (2023)
EP06.03-08 Clinical Study to Molecularly Profile Filipino Lung Adenocarcinoma
Authors: F.M. Heralde, M. Cabanatan, K. Fernandez, M.P. Apelado, N. Tan-Liu, G. Ladrera, J. Danguilan, M.R. Alvarez, I. Padolina, J. Rabajante, C. Lebrilla, R. Nacario, G. Completo, M.T.A. Barzaga
Journal: Journal of Thoracic Oncology (2023)
MA18.04 Prognostic Factors in Limited-Stage Small Cell Lung Cancer (LSCLC) : Secondary Analysis of CALGB 30610 (Alliance)/RTOG 0538
Authors: M.K. Farris, M. Mix, X. Wang, B.L. Jaszewsk, N. Foster, G. Masters, F. Laurie, K. Smith, N. Razavian, R. Alden, R. Komaki, T. Stinchcombe, J. Bradley, E. Vokes, J. Bogart
Journal: Journal of Thoracic Oncology (2023)
MA15.09 Ph 2 Trial of IO102-IO103 Vaccine Plus Pembrolizumab: Preliminary Results for the First-line Treatment of Lung Adenocarcinoma
Authors: J.W. Riess, E. Cohen, J. Vuky, P. Shaw, J. Rubio, L.M. Rodriguez, M.F. Chaney, S. O'Neill, A. Alavi, D.O. McDowell, E. Ehrnrooth, P. Garrido
Journal: Journal of Thoracic Oncology (2023)
A pragmatic, open-label, randomized controlled trial of Plasma-Lyte-148 versus standard intravenous fluids in children receiving kidney transplants (PLUTO).
Authors: Wesley N. Hayes, Emma Laing, Rosemary Brown, Laura Silsby, Laura Smith, Helen Thomas, Fotini Kaloyirou, Rupa Sharma, James Griffiths, Helen Hume-Smith, Stephen D. Marks, Nicos Kessaris, Martin Christian, Jan Dudley, Mohan Shenoy, Michal Malina, Mordi Muorah, Nicholas Ware, Pallavi Yadav, Ben Reynolds, William Bryant, Anastassia Spiridou, Jo Wray, Mark J. Peters
Journal: Kidney International (2023)

Acute electrolyte and acid-base imbalance is experienced by many children following kidney transplant. This is partly because doctors give very large volumes of artificial fluids to keep the new kidney working. When severe, fluid imbalance can lead to seizures, cerebral edema and death. In this pragmatic, open-label, randomized controlled trial, we randomly assigned (1:1) pediatric kidney transplant recipients to Plasma-Lyte-148 or standard of care perioperative intravenous fluids (predominantly 0.45% sodium chloride and 0.9% sodium chloride solutions). We then compared clinically significant electrolyte and acid-base abnormalities in the first 72 hours post-transplant. The primary outcome, acute hyponatremia, was experienced by 53% of 68 participants in the Plasma-Lyte-148 group and 58% of 69 participants in the standard fluids group (odds ratio 0·77 (0·34 - 1·75)). Five of 16 secondary outcomes differed with Plasma-Lyte-148: hypernatremia was significantly more frequent (odds ratio 3·5 (1·1 - 10·8)), significantly fewer changes to fluid prescriptions were made (rate ratio 0·52 (0·40-0·67)), and significantly fewer participants experienced hyperchloremia (odds ratio 0·17 (0·07 - 0·40)), acidosis (odds ratio 0·09 (0·04 - 0·22)) and hypomagnesemia (odds ratio 0·21 (0·08 - 0·50)). No other secondary outcomes differed between groups. Serious adverse events were reported in 9% of participants randomized to Plasma-Lyte-148 and 7% of participants randomized to standard fluids. Thus, perioperative Plasma-Lyte-148 did not change the proportion of children who experienced acute hyponatremia compared to standard fluids. However fewer fluid prescription changes were made with Plasma-Lyte-148, while hyperchloremia and acidosis were less common.
MA10.06 CARMA-BROS: CAncers with Rare Molecular Alterations - Basket-umbrella Real-world Observational Study
Authors: F. Al Agha, S. Raptis, L.J. Zhan, S.H. Barghout, D. Patel, M.C. Brown, W. Xu, C. Ho, W. Cheung, D. Dawe, S. Banerji, S. Kuruvilla, P. Cheema, I. Menjak, R. Burkes, K. Jao, A. Fung, N. Blais, J. Agulnik, N. Bouchard, L. Galvis, R.A. Juergens, P. Wheatley-Price, S. Moore, S. Snow, G. Liu
Journal: Journal of Thoracic Oncology (2023)
A CT-based radiomics classification model for the prediction of histological type and tumour grade in retroperitoneal sarcoma (RADSARC-R): a retrospective multicohort analysis
Authors: Amani Arthur, Matthew R Orton, Robby Emsley, Sharon Vit, Christian Kelly-Morland, Dirk Strauss, Jason Lunn, Simon Doran, Hafida Lmalem, Axelle Nzokirantevye, Saskia Litiere, Sylvie Bonvalot, Rick Haas, Alessandro Gronchi, Dirk Van Gestel, Anne Ducassou, Chandrajit P Raut, Pierre Meeus, Mateusz Spalek, Matthew Hatton, Cecile Le Pechoux, Khin Thway, Cyril Fisher, Robin Jones, Paul H Huang, Christina Messiou
Journal: The Lancet Oncology (2023)
OA05.05 Ifinatamab Deruxtecan (I-DXd; DS-7300) in Patients with Refractory SCLC: A Subgroup Analysis of a Phase 1/2 Study
Authors: M. Johnson, M. Awad, T. Koyama, M. Gutierrez, G.S. Falchook, S.A. Piha-Paul, T. Doi, T. Satoh, N. Okamoto, J. Singh, N. Yoshizuka, M. Qian, X. Qian, B.P. Tran, O. Dosunmu, R. Mucha, H. Windish, M.R. Patel
Journal: Journal of Thoracic Oncology (2023)
OA11.06 Sublobar Resection vs. Lobectomy for Non-Small-Cell Lung Cancers 2cm or Less in Size with High-Risk Features
Authors: C.A. Mathey-Andrews, S. Venkateswaran, A. Abruzzo, A. Potter, C. Haridas, A. Kumar, V. Raman, C.-F.J. Yang
Journal: Journal of Thoracic Oncology (2023)
WS02.20 Upregulation of HLA-I/II and Pro-inflammatory Cells in PBMCs Indicated Efficacy of Neoadjuvant Chemo-immunotherapy in Locally Advanced NSCLC
Authors: L. Hou, T. Hu, J. Wang, T. Sun, C. Zhu, C. Wu, H.K. Xie
Journal: Journal of Thoracic Oncology (2023)
EP12.01-51 Clinical Significance of Chronic Interstitial Pneumonia Induced by EGFR-TKI Administration
Authors: Y. Sato, F. Kanazawa, R. Tachikawa, S. Hara, C. Shirakawa, R. Hirabayashi, K. Nagata, A. Nakagawa, K. Tomii
Journal: Journal of Thoracic Oncology (2023)
MA10.04 Evaluation of a Risk-Sharing Agreement for Atezolizumab Treatment in NSCLC Patients: A Strategy to Improve Access in Low Income Countries
Authors: O. Arrieta, M. Ramos-Ramirez, H. Garces-Flores, L.A. Cabrera-Miranda, A. Valencia-Velarde, A. Frias-Gasga, H. Soto-Molina
Journal: Journal of Thoracic Oncology (2023)
OA07.05 Pre-Recruitment as a Strategy to Address “Near-Miss” Cases in Risk-Based Lung Cancer Screening Selection: An Analysis of ILST Data
Authors: C. Kumarasamy, K. Betts, R. Norman, A. McWilliams, E. Stone, R. Manser, P. Fogarty, H. Marshall, S. Lam, M. Tammemagi, K. Fong, F. Brims
Journal: Journal of Thoracic Oncology (2023)
Re: Bhavan P. Rai, José Luis Dominguez Escrig, Luís Vale, et al. Systematic Review of the Incidence of and Risk Factors for Urothelial Cancers and Renal Cell Carcinoma Among Patients with Haematuria. Eur Urol 2022;82:182–92
Authors: Qingpeng Xie, Dianqiu Shen
Journal: European Urology (2023)
Analytical interference with most current commercial HIV molecular assays in patients treated by idecabtagene vicleucel, a recently approved lentivirus-based chimeric antigen receptor T-cell therapy
Authors: Charlotte Pronier, Karl Stefic, Hélène Le Guillou Guillemette, Mikael Roussel, Vincent Thibault, Anne Maillard
Journal: Clinical Microbiology and Infection (2023)
MA17.06 Surgical Results of EORTC 1205, a Randomized Phase II Study of Surgery for Mesothelioma Preceded or Followed by Chemotherapy
Authors: J. Raskin, A.P.W.M. Maat, V. Surmont, S.A. Burgers, M. Yahia, Y. Pretzenbacher, R. Cornelissen, F. De Ryck, H.M. Klomp, S. Marreaud, P. Baas, J. Aerts, A. Oliveira, J.P. Van Meerbeeck, P. van Schil
Journal: Journal of Thoracic Oncology (2023)
EP17.03-01 Quantitative Findings from a Survey of Health Insurance in Patients Diagnosed as Advanced Lung Cancer in Japan
Authors: K. Kinoshita, T. Sato, F. Ito, K. Horiuchi, D. Arai, K. Ohgino, K. Ishioka, H. Terai, S. Ikemura, H. Yasuda, I. Nakachi, I. Kawada, T. Inoue, Y. Oyamada, T. Terashima, K. Sayama, D. Fujisawa, M. Takeuchi, K. Fukunaga, K. Naoki, K. Soejima
Journal: Journal of Thoracic Oncology (2023)
EP14.01-03 Cytologic Predictors and Novel Markers of Malignant Mesothelial Proliferation (mesothelioma) in Pleural Effusion
Authors: P. Viola, H. Kudo, G. Valentine, G. Srilal, J. Vidak, H. Ahmed, F. Reza-Sanjani, A. De Silva, P.M. Tsang, M.A. Montero Fernandez, C. Wright
Journal: Journal of Thoracic Oncology (2023)
OA02.05 Dendritic Cell Immunotherapy Versus Best Supportive Care as Maintenance Treatment in Patients with Pleural Mesothelioma
Authors: J.G.J.V. Aerts, B. Belderbos, P. Baas, A. Scherpereel, R. Berardi, D. Fennell, R. Kerstens, R. Cornelissen, J. van Meerbeeck
Journal: Journal of Thoracic Oncology (2023)
EP13.07-08 Canadian Consensus Recommendations: Use of Radiation Therapy among Patients with ES-SCLC receiving Immunotherapy
Authors: A. Sun, B. Abdulkarim, N. Blais, J. Greenland, A. Louie, B. Melosky, D. Schellenberg, S. Snow, G. Liu
Journal: Journal of Thoracic Oncology (2023)
EP12.02-11 Sequencing Patterns and Treatment Effectiveness in ALK-positive aNSCLC Following First-Line Alectinib or Brigatinib
Authors: I. Preeshagul, D. Abrahami, B. Li, D. Thomaidou, K. Duncan, S. Krulewicz, M. Rupp, J. Bauman
Journal: Journal of Thoracic Oncology (2023)
EP13.03-02 Improved Long-Term Survival and Less Chemotherapy in Extended-SCLC Patients: A Real-World Study in the Immunotherapy Era
Authors: L. Calvetti, G. Sartori, F. Pancheri, F. Simionato, M. Cosci, S. Scarparo, A.G. Menin, I. Posenato, D. Reghellin, A. Tisato, S. Ave, G. Aprile
Journal: Journal of Thoracic Oncology (2023)
EP14.01-02 Treatment Response in Malignant Pleural Mesothelioma Patients Can Be Predicted by Exhaled Breath Analysis
Authors: K. Lamote, E. Heirwegh, E. Schillebeeckx, E. Janssens, V. Surmont, K. Nackaerts, E. Marcq, J.P. van Meerbeeck
Journal: Journal of Thoracic Oncology (2023)
OA03.04 A Phase 1b Study Of Furmonertinib, an Oral, Brain Penetrant, Selective EGFR Inhibitor, in Patients with Advanced NSCLC with EGFR Exon 20 Insertions
Authors: B. Han, C. Zhou, W. Zheng, L. Wu, Z. Ma, H. Wang, X. Yu, G. Ding, D. Ma, L. Nie, Z. Zhang, X. Dong, Y. Shang, K. Tang, W. Zhang, J.Y. Hsu, Y. Jiang, Q. Zhao
Journal: Journal of Thoracic Oncology (2023)
EP12.02-12 Matching-Adjusted Indirect Comparison (MAIC): Entrectinib versus Crizotinib in Asian Patients with ROS1+ NSCLC
Authors: S. Lu, Y. Fan, Y. Yu, X. Dong, J. Li, J. Zhao, S. Tao, M. Chen, Y. Chen, Y. Liu, J. Xu, X. Hu
Journal: Journal of Thoracic Oncology (2023)
First-in-human phase I/Ib study of NIZ985, a recombinant heterodimer of IL-15 and IL-15Rα, as a single agent and in combination with spartalizumab in patients with advanced and metastatic solid tumors
Authors: Rom Leidner, Kevin Conlon, Douglas G McNeel, Andrea Wang-Gillam, Sumati Gupta, Robert Wesolowski, Monica Chaudhari, Nadia Hassounah, Jong Bong Lee, Lang Ho Lee, Jessica A O’Keeffe, Nancy Lewis, George N Pavlakis, John A Thompson
Journal: Journal for ImmunoTherapy of Cancer (2023)

Background Preclinically, interleukin-15 (IL-15) monotherapy promotes antitumor immune responses, which are enhanced when IL-15 is used in combination with immune checkpoint inhibitors (ICIs). This first-in-human study investigated NIZ985, a recombinant heterodimer comprising physiologically active IL-15 and IL-15 receptor α, as monotherapy and in combination with spartalizumab, an anti-programmed cell death protein-1 (anti-PD-1) monoclonal antibody, in patients with advanced solid tumors. Methods This phase I/Ib study had two dose-escalation arms: single-agent NIZ985 administered subcutaneously thrice weekly (TIW, 2 weeks on/2 weeks off) or once weekly (QW, 3 weeks on/1 week off), and NIZ985 TIW or QW administered subcutaneously plus spartalizumab (400 mg intravenously every 4 weeks (Q4W)). The dose-expansion phase investigated NIZ985 1 µg/kg TIW/spartalizumab 400 mg Q4W in patients with anti-PD-1–sensitive or anti-PD-1–resistant tumor types stratified according to approved indications. The primary objectives were the safety, tolerability, and the maximum tolerated doses (MTDs) and/or recommended dose for expansion (RDE) of NIZ985 for the dose-expansion phase. Results As of February 17, 2020, 83 patients (median age: 63 years; range: 28–85) were treated in dose escalation (N=47; single-agent NIZ985: n=27; NIZ985/spartalizumab n=20) and dose expansion (N=36). No dose-limiting toxicities occurred nor was the MTD identified. The most common treatment-related adverse event (TRAE) was injection site reaction (primarily grades 1–2; single-agent NIZ985: 85% (23/27)); NIZ985/spartalizumab: 89% [50/56]). The most common grade 3–4 TRAE was decreased lymphocyte count (single-agent NIZ985: 7% [2/27]; NIZ985/spartalizumab: 5% [3/56]). The best overall response was stable disease in the single-agent arm (30% (8/27)) and partial response in the NIZ985/spartalizumab arm (5% [3/56]; melanoma, pancreatic cancer, gastric cancer). In dose expansion, the disease control rate was 45% (5/11) in the anti-PD-1–sensitive and 20% (5/25) in the anti-PD-1–resistant tumor type cohorts. Pharmacokinetic parameters were similar across arms. The transient increase in CD8+ T cell and natural killer cell proliferation and induction of several cytokines occurred in response to the single-agent and combination treatments. Conclusions NIZ985 was well tolerated in the single-agent and NIZ985/spartalizumab regimens. The RDE was established at 1 µg/kg TIW. Antitumor activity of the combination was observed against tumor types known to have a poor response to ICIs. Trial registration number NCT02452268 .
OA11.05 A Propensity-Matched Comparison between Minimally Invasive Surgery and Stereotactic Radiotherapy in the Treatment of Clinical Stage I NSCLC
Authors: E. Farinelli, N. Daddi, P. Bertoglio, M. Lugaresi, L. Valentini, S. Volpi, G. Fabbri, F. Salvi, G.P. Frezza, G. Dolci, J. Brandolini, E. Josephides, S. Ahmad, D. Smith, P. Solli, A. Billè
Journal: Journal of Thoracic Oncology (2023)
EP13.04-01 Efficacy of Prophylactic Cranial Irradiation According to the Risk of Extracranial Recurrence in Limited-Stage Small Cell Lung Cancer
Authors: T.H. Lee, J.-H. Chung, H.-G. Wu, S. Kim, J.H. Lee, B. Keam, J.-S. Kim, K.H. Kim, B.H. Kim, H.J. Kim
Journal: Journal of Thoracic Oncology (2023)
EP12.01-42 Long-term Survivors with EGFR Positive Non-Small Cell Lung Cancer Treated with Tyrosine Kinase Inhibitors: A Combined Canadian Cohort
Authors: H. Halperin, A.J.W. Gibson, M. Sung, P. Tomasini, M. Dean, J. Law, W.Y. Cheung, N. Leighl, D. Hao
Journal: Journal of Thoracic Oncology (2023)